Accueil   Agenda - News   Toutes les news Pierre Fabre Pharmaceuticals and BioSerenity join forces to develop the first connected fabric for the detection and medical monitoring of urinary disorders

Pierre Fabre Pharmaceuticals and BioSerenity join forces to develop the first connected fabric for the detection and medical monitoring of urinary disorders

 

 

CASTRES (France). - May 14th, 2018 - Pierre Fabre Pharmaceuticals and French startup BioSerenity announced the signature of an agreement on the co-development, market access and distribution of connected medical devices for managing urinary incontinence. This agreement follows an initial collaboration phase launched at the end of 2016, during which several connected fabric prototypes were developed by BioSerenity with the assistance of staff from Pierre Fabre Pharmaceuticals. The new phase of this partnership will concern the manufacture and marketing of a connected fabric that will diagnose, assess and carry out medical monitoring of urinary disorders caused by an overactive bladder. This chronic illness affects almost 20% of men and women over the age of 40, whose daily lives are severely marred by this pathology.

 

 

The connected fabric, in underwear form, is worn around the abdominal area. With its biometric sensors recording the various operating parameters of the urinary device, it continuously detects and quantifies the patient's urinary problems, then forwards the readings recorded on a mobile app to a secure Cloud platform that can be consulted by the urologist for ongoing medical monitoring.

 

 

According to the terms of the agreement, Pierre Fabre Pharmaceuticals will co-finance R&D for this connected device. Subsequently, Pierre Fabre will have exclusive selling rights for the system in France and worldwide. The financial terms were not revealed.

 

 

Read the press release

 

 

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer